N/A N=6 Pilot Trial of Contingency Management for Long-Term Cannabis Abstinence
Cannabis Use · Adolescent Behavior
Primary: Continuous Abstinence Via Progressive Declines in Urine THCCOOH — NA ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=95 FirstStep2Health Intervention
Pediatric Obesity · Risk Reduction Behavior · Early Intervention
Primary: Moderate-to-vigorous Physical Activity (MVPA; Preschoolers)-AIM 1 — 7.51; 7.46 Minutes per hour
N/A N=74 Experiential HIV Testing Increasing Testing Related Knowledge and Practice, and Reduce Stigma Toward HIV of Nurses.
Hiv · HIV Testing
Primary: HIV Testing Related Knowledge and Practice — 17.17; 17.22; 19.44; 17.36 score on a scale — p=<0.001
Phase 1 N=74 Study of Oral Edaravone in Healthy Adult Males
Healthy Adult Subjects
Primary: Number of Participants With Adverse Events (Aes) and Adverse Drug Reactions (ADRs) — 0; 2; 3; 0 Participants
N/A N=27 Effects of Exercise Training on Pelvic Floor Symptoms and Function in Adults With Constipation
Constipation
Primary: Severity of Constipation Symptoms — 0.96; 0.97; 0.63; 0.67 score on a scale
Phase 1 N=78 Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide. — 161; 165; 532; 482 ng*h/mL
Phase 1 N=80 A Study of TAK-105 in Healthy Adults
Healthy Volunteers
Primary: Number of Participants With At Least One Treatment-emergent Adverse Event (TEAEs) — 6; 3; 4; 3 Participants
Phase 3 N=453 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
Epithelial Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 5.59; 3.98 months — p=<0.0001
Phase 3 N=307 Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — -0.4; 8.9 percent predicted FEV1 — p=< 0.0001
N/A N=2,196 Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention
Transplant
Primary: Any Hospitalization or Any Emergency Room Visits — 497; 574; 380; 391 Participants — p=<.001
N/A N=10 iTBS in Bipolar I Depression
Bipolar Depression · Bipolar I Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score — 16.9 score on a scale
N/A N=316 Online and Shared Decision-Making Interventions to Engage Service Men and Women in Post-Deployment Mental Health Care
PTSD · Depression · Substance Use Disorder
Primary: VA Mental Health Treatment Engagement Validated by Self Report or VA Electronic Medical Record Review. — 98; 7 Participants — p=<0.00001
N/A N=27 SI + CC Versus 3:1 C:V Ratio During Neonatal CPR
Heart Arrest · Birth Asphyxia · Bradycardia
Primary: Return of Spontaneous Circulation — 90; 615 seconds
Phase 3 N=32 Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.
Central Precocious Puberty
Primary: Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation — 100 percentage of participants
Phase 4 N=46 Touch and Feel Evaluation of Two Foam Hand Sanitizers
Hand Hygiene
Primary: Primary Objective Foam Sanitizer User Touch and Feel Experience — 53.21; 39.62; 61.21; 49.73 score on a scale